as usual on a stock deal the two stocks are trading in tandem. teva is unusually strong, this is more than likely because of it being a partial cash deal among other things. do not short brl unless it breaks below the open and teva is still in tandem.
this is not a recommendation for you to trade, merely an example. do not trade on the stockman's info alone. seek professional advice before day trading for suitability etc.
If you found this article interesting please subscribe for updates with any reader or your email. This site is not monetized and 100 percent free. My only form of payment is my readers comments and subscriptions
Friday, July 18, 2008
Teva Barr buyout, BRL fade update
Teva to buy Barr for $7.46 billion, boost generic lead
We have another cash and stock deal, two this week!!.
BRL is gapping up nicely and could be another great fade opportunity.
NEW YORK (Reuters) - Teva Pharmaceutical Industries (TEVA.O: Quote, Profile, Research) (TEVA.TA: Quote, Profile, Research) said on Friday it would buy rival generic drugmaker Barr Pharmaceuticals Inc (BRL.N: Quote, Profile, Research) for $7.46 billion to expand its leadership in the U.S. market and fortify its presence in Europe.
The deal is the latest in a wave of consolidation in the generic-drug sector that some analysts suspect will result in only a handful of major global players.
Israel-based Teva, the world's largest generic drug company, plans to buy New Jersey-based Barr for $66.50 per share in cash and stock.
The price represents a 42 percent premium to Barr's closing price on Wednesday. Barr shares rose 22 percent on Thursday on reports of a Teva acquisition.
In pre-market trading on Friday, Barr shares rose 6.7 percent to $60.99, while Teva shares fell 4.4 percent to
$39.25.
The combined company would be a generic powerhouse employing about 37,000 people globally and operating directly in more than 60 countries. Together, Barr and Teva had revenue of about $11.9 billion in 2007.
By acquiring Barr, No. 5 in the U.S. in generic prescriptions, Teva would move closer to its stated goal of boosting its U.S. market share to 30 percent of generic prescriptions by 2012, from about 20 percent. Continued...
Teva to buy Barr for $7.46 billion, boost generic lead | Reuters
If you found this article interesting please subscribe for updates with any reader or your email. This site is not monetized and 100 percent free. My only form of payment is my readers comments and subscriptions
Pre Market Trader Talk with Bob Pisani
Is there any doubt that big-cap financials are the key to this market? Despite earnings below expectations for Microsoft[MSFT 27.52 --- UNCH (0) 
] and Google[GOOG 533.44 --- UNCH (0) ], and a large writedown from Merrill Lynch, [MER 30.73 --- UNCH (0) ]it was Citigroup beating expectations that moved futures up almost 15 points this morning.
This is crunch time for this little mini-rally--since the earnings news is mixed, it will be critical for the market to move sideways or up today, and avoid retracing any of the last two days gains.
Options expiration today.
Citi's[C 17.97 --- UNCH (0) ] loss of $0.49 was better than the loss of $0.66 expected. Doesn't sound great, but things are getting better: they reported a loss of $1.02 in the first quarter, and a loss of $1.99 in the fourth quarter. Yes, there was $7.2 billion in writedowns, but even that is an improvement. As with Wells Fargo,[WFC 27.83 --- UNCH (0) ] net interest margin was a bit higher than expected. Up 9 percent pre-open.
Elsewhere:
1) Freddie Mac [FRE 8.33 --- UNCH (0) ]still trading up, despite the fact that the WSJ reported they were considering raising up to $10 billion in equity through a sale of common and preferred stock.
2) Meantime, Honeywell [HON 50.86 --- UNCH (0) ]beat on topline and revenues, and raised their guidance (it's in-line with estimates).
Aerospace sales (about a third of sales) were strong. Remember, all the aerospace companies got slammed in June on concerns that aerospace sales would be slowing globally. Up 4 percent pre-open.
3) Mattel [MAT 18.28 --- UNCH (0) ]also beat expectations, up 12 percent.
4) Bank and credit card giant Capital One [COF 42.80 --- UNCH (0) ]reported earnings below expectations, down 2 percent pre-open.
5) Barr Labs[BAR 0.16 
-0.005 (-3.03%) ], which had been a speculated takeover target for a couple days, is being bought by Teva for $7.46 billion, about $66.50 in cash and stock, a 42 percent premium to Barr's closing price on Wednesday. Teva is the largest generic drug maker in the world.
Key To Market? Big Cap Financials - Trader Talk with Bob Pisani - CNBC.com
Opening View: Citigroup Beats Forecast, Merrill Lynch Posts Hefty Loss
Citigroup (C: 
sentiment, chart, options) , following in the footsteps of Wells Fargo (WFC) and J.P. Morgan Chase (JPM), this morning reported stronger-than-expected earnings. The financial firm reported that it lost $2.5 billion, or 54 cents per share, in the second quarter, better than the 66-cent-per-share loss analysts were expecting. The company reported write-downs of about $8 billion – significantly lower than the write-downs recorded in the first and fourth quarters. However, the banking behemoth said that credit costs jumped to $7.2 billion in the wake of more consumers defaulting on their loans.
Meanwhile, Merrill Lynch (MER: sentiment, chart, options) after the close yesterday reported a second-quarter loss of $4.89 billion, or $4.97 per share. Analysts, on average, were predicting a loss of $1.91 per share. What's more, the company reported nearly $40 billion in write-downs related to failed investments. Since stepping into the earnings spotlight, the firm has been bombarded by analysts. Moody's Investment Services downgraded the senior long-term debt of MER to "A2" from "A1;" Fox-Pitt cut the firm's rating to "underperform" from "in line;" Goldman Sachs cut the company's 6-month price target to $33 from $38; Bernstein reduced its price target on the equity to $30 from $45; and Banc of America cut its price target to $47 from $55, among others.
Rounding out the earnings trifecta is Microsoft (MSFT: sentiment, chart, options) , which reported fiscal fourth-quarter earnings of $4.3 billion, or 46 cents per share – 3 pennies below the average analyst estimate. Revenue, however, jumped 18% to $15.8 billion, just ahead of the Street's forecast for revenue of $15.7 billion. For the fiscal year, earnings rose 26% to $17.7 billion, or $1.87 per share, while sales came in at $60.4 billion. For the current quarter, MSFT predicted earnings of 47 cents to 48 cents per share on revenue of $14.7 billion to $14.9 billion – just shy of the Street's projections for earnings of 49 cents per share on $15.1 billion in sales.
Opening View: Citigroup Beats Forecast, Merrill Lynch Posts Hefty Loss
NYSE Arca Morning Update
Stocks trading on NYSE Arca at a price more than 15% away from the previous trade day's consolidated close price. (As of 08:30:00 ET)
Stock | Thursday's Close | Current Price | Pct Chng | Current NYSE Arca Vol |
|---|---|---|---|---|
G | $13.47 | $29.55 | 119% | 5,000 |
SGLP | $11.00 | $8.01 | ( 27%) | 39,860 |
10 Most Active stocks on NYSE Arca as of 08:30:00 ET
| Based on Dollar Volume: | Based on Share Volume: | ||||||||||||||||||||||||||||||||||||||||||||
|
|
SGLP:
- SemGroup faces cash crunch, considers optionsAP(Fri 7:49am)
- SEMGROUP ENERGY PARTNERS, L.P. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Fri 6:01am)
NYSE Arca Morning Update
Pre-Market Trading Most Active Stocks - NASDAQ Premarket
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pre-Market Most Active Stocks - NASDAQ Premarket
Subscribe to:
Posts (Atom)
